United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference
The presentation will take place on
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
James Edgemond at (301) 608-9292, Email: firstname.lastname@example.org